Compare Ascendis Pharma A/S (ASND) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Vanguard Information Technology Index Fund ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Vanguard Information Technology Index Fund ETF trades at $117.29. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Vanguard Information Technology Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| ASND | VGT | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | — |
52-Week High | $277.18 | $125.77 |
52-Week Low | $163.32 | $83.59 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
VGT trades at $118.08, up 0.31% with a bullish technical signal from moving averages. The ETF shows strong institutional backing and positive media coverage highlighting its tech sector exposure and low 0.09% expense ratio. Recent news emphasizes VGT's outperformance versus QQQ and its role in AI-driven tech investments.
Outlook remains positive given tech sector momentum and AI growth catalysts, though risks include sector volatility and valuation concerns. Analyst sentiment favors VGT for broad tech diversification with competitive fees supporting long-term growth potential amid market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
